Miscellaneous Products Infusion Therapy Site-of-Care Prior Authorization
Customize your policy alerts
Sign up for Providence Health Plan Policy ORPTCOTH030 alerts
Get alerted when Policy ORPTCOTH030 changes without checking for updates manually.
Monitor payer policy activity
Policy governs prior authorization and site-of-care requirements for administration of specified infusion medications for Providence Health Plan commercial members aged 13 and older, defining approved and unapproved infusion settings and criteria for allowing administration in unapproved hospital outpatient infusion centers.
No material clinical or coverage changes in this revision.
Coverage Criteria and Medical Necessity
Medical necessity exceptions for unapproved site
Unapproved hospital-based outpatient infusion center may be considered medically necessary if ANY of the following are met:
Examples include recent documented severe adverse drug reactions or anaphylaxis; concomitant complex medical conditions (e.g., antibodies increasing infusion reaction risk, severely compromised cardiac or respiratory function); use of multiple concurrent therapies requiring higher level care (for example cytotoxic chemotherapy or CAR‑T administered over the same treatment period); chronic vascular access complications requiring hospital-based interventions/equipment; mental health or cognitive changes requiring higher level care
Home ineligibility examples include the member's home being outside the infusion provider's service area, or upon inspection the home is considered unfit or unsafe for home infusion services
Initial dose exceptions
Site-of-care criteria shall be waived for the administration of the first dose for all drugs; additional limited doses for certain drugs may be allowed to assess tolerability in higher level care:
Select drugs (for example certain enzyme replacement therapies and oncology immunotherapies) may be permitted additional doses at a non-approved site to assess tolerability; the number of additional doses is established based on the drug safety profile and manufacturer recommendations and is listed in the HCPCS drug table
Position statement — alternate-site infusion
Policy position and clinical rationale for alternate-site infusion
Supports alternate-site infusion as cost-effective with similar clinical outcomes and high patient preference; individual product coverage and site exceptions continue to be reviewed per medical necessity and the infused medication list is subject to change
The policy specifies Exclusion Criteria: N/A. No specific exclusions are listed in this segment of the policy.
There are no explicit product exclusions noted in this portion of the document; the infused medication list is subject to change. Individual medications and any future exclusions will be handled through updates to the policy and reviewed on a case-by-case basis.
Administration in an unapproved hospital outpatient infusion setting is considered not medically necessary when an approved site of care is available and the unapproved setting is determined to be no longer medically necessary. Use of an unapproved hospital outpatient infusion center should therefore be limited to circumstances meeting the policy's medical necessity exceptions or when an approved site is unavailable.
This segment does not enumerate additional explicit not medically necessary conditions beyond the general denial trigger; however, exceptions to site-of-care determinations are reviewed individually and denials may occur when exception criteria or supporting documentation are not provided.
HCPCS/J/Q Codes and Dose Exceptions
| J0791 | Adakveo (crizanlizumab) — New Start Dose Exceptions = 1 |
| J1931 | Aldurazyme (laronidase) |
| J1552 | Alyglo (immune globulin) — New Start Dose Exceptions = 1 |
| J1426 | Amondys 45 (casimersen) — New Start Dose Exceptions = 1 |
| J0225 | Amvuttra (vutrisiran) — New Start Dose Exceptions = 1 |
| J0256 | Aralast NP / Prolastin-C / Zemaira (alpha-1 proteinase inhibitor) — New Start Dose Exceptions = 1 |
| J0881 | Aranesp (darbepoetin alfa) — New Start Dose Exceptions = 1 |
| J1554 | Asceniv (immune globulin) — New Start Dose Exceptions = 1 |
| Q5121 | Avsola (infliximab-axxq) — New Start Dose Exceptions = 1 |
| J9023 | Bavencio (avelumab) |
| J1305 | Evinacumab |
| J1428 | Evkeeza / Exondys 51 / Eteplirsen (entries present) |
| J0180 | Fabrazyme / agalsidase beta |
| J9395 | Faslodex / fulvestrant |
| J9394 | Fresenius Kabi / fulvestrant |
| J1569 | 505(b)(2) Gammagard |
| J1561 | Gammagard ERC / Gammaked / immune globulin |
| J1557 | Gamunex-C / Gammaplex / immune globulin |
| J0223 | Givlaari / givosiran |
| J0257 | Glassia / alpha-1 proteinase inhibitor |
Provider Requirements and Authorization Actions
Prior authorization required when applicable
Obtain prior authorization for the medication when required; note that authorization decisions for clinical criteria are separate from decisions about use of an unapproved hospital outpatient infusion center.
PA required for listed HCPCS/J/Q infusion products
Submit prior authorization requests for the listed HCPCS/J/Q infusion products and include any applicable 'New Start Dose Exceptions' allowance for initial dosing as specified for each product.
First‑dose waiver and arrange transition to approved site
If an approved site is not yet arranged, the first dose may be administered at an unapproved site to allow time to transition the member to an approved alternative site; additional limited new‑start doses are permitted only as specified per drug.
Alternate‑site infusion favored; no mandated step‑therapy
Preference is for alternate‑site infusion (home or specialty infusion) as a cost‑effective, clinically comparable option; the policy does not impose specific step‑therapy sequencing or mandatory medication failures.
Document clinical need and administration notes for PA and reauthorization
Include prior authorization (when required) plus clinical and administration notes that document the continued need for the unapproved site; reauthorization requires six‑month clinical/administration documentation and consideration of transfer to available approved sites.
- Clinical justification for why the unapproved site is necessary (e.g., one of the medical necessity exception criteria)
- Administration notes from the past six months for reauthorization
- Documentation of attempts/plan to transfer to an approved site, if applicable
Include HCPCS code and new‑start dose exception on PA
Reference the specific HCPCS/J/Q code for the infused product on the prior authorization request and document any New Start Dose Exceptions used (e.g., '4 doses within 60 days' or '6 doses within 90 days') consistent with the HCPCS table.
- Specify HCPCS/J/Q code for the requested product
- State the new‑start dose allowance being applied (per the listed exception for that code)
Risk of denial for unapproved hospital outpatient infusion
Claims for administration in an unapproved hospital outpatient infusion setting may be denied when an approved site of care is available and the unapproved setting is not justified by documented medical necessity.
Exceptions reviewed individually; insufficient support may cause denial
Request site‑of‑care exceptions will be reviewed case‑by‑case; failure to provide documentation that meets the medical‑necessity exception criteria or home‑ineligibility reasons may result in denial.
- Provide documentation matching one of the unapproved‑site medical necessity criteria (e.g., recent severe adverse reaction, need for hospital‑level equipment, home deemed unsafe or out of service area)
- If invoking a New Start Dose Exception, document the specific exception and clinical rationale
Definitions
Initial Therapy Site-of-Care Exceptions
Initial therapy allowances
Initial therapy site-of-care exceptions
Certain drugs have additional allowed new-start doses as specified in the HCPCS tables (see drug-specific New Start Dose Exceptions)
Initial therapy — new start dose exceptions
Initial authorization may use New Start Dose Exceptions as specified per HCPCS code.
Exact numeric allowances are listed in the HCPCS/drug tables in this policy and should be applied for initial authorizations; clinical eligibility criteria for each drug are addressed in individual drug policies
Reauthorization and Continuation Requirements
Reauthorization
Reauthorization occurs every six months and requires documentation of continued clinical need and consideration of available approved sites for transfer.
Reauthorization decisions will include consideration of transfer to any newly available approved sites of care; approvals may be up to one year per authorization
Site-of-Care Transition and Step Therapy
| Step | Requirement / Action |
|---|---|
| 1 | |
| Transition to the most affordable medically appropriate site of care when an approved site is available; initial dosing/first‑dose exceptions permitted to allow arrangement of an approved site of care |
| Step | Details |
|---|---|
| 0 | |
| No explicit step‑therapy sequencing, mandatory trial/failure requirements, or ordered therapeutic steps are specified in this policy segment; the policy emphasizes preference for alternate‑site (home/infusion suite) care when clinically appropriate |
Approved and Alternate Sites of Care
Administer at approved site when available; first-dose waiver and select exceptions apply
Specified drugs require administration at an approved site of care when an approved site is available; the policy waives the site-of-care requirement for the first dose and provides select additional New Start Dose Exceptions for certain products.
- First-dose waiver applies for all drugs to allow arranging an approved site.
- Select HCPCS-coded products have per-code New Start Dose Exceptions as listed in the policy.
Support for home or alternate-site infusion
Alternate-site infusion (home or the home-infusion provider's suite) is supported as cost‑effective and clinically appropriate for many patients and is preferred when clinically appropriate.
- Policy states home and alternate-site infusion are cost‑effective and have comparable clinical outcomes.
Background and Rationale
Historically, infusion therapy was delivered in outpatient hospital facilities but has increasingly shifted to alternative sites (provider office, stand-alone infusion centers, or patient home) driven by cost-effectiveness and patient preference. The policy supports alternate-site infusion when clinically appropriate and notes studies showing increased home infusion utilization and generally low rates of serious infusion reactions in monitored alternative settings; exceptions to site-of-care determinations are reviewed case-by-case and the infused medication list may guide which products are suitable for non-hospital settings.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.